Bioprojet published a study showing that somnolence diurne excessive résiduelle (SDEr) is associated with cognitive impairments in patients with sleep apnea-hypopnea obstructive syndrome (SAHOS), including memory, executive functions, attention, and information processing speed.

Bioprojet is a pharmaceutical laboratory committed to science and health. In the last 40 years, we’ve brought forward breakthrough medicines, helping patients struggling with challenging diseases. With passion and integrity, we follow the path set by Jeanne-Marie Lecomte and Jean-Charles Schwartz, founders of Bioprojet. At Bioprojet, we grow to keep honoring our motto : Passion for Research. Research for Patients. Read our terms of use ➡️ https://bit.ly/3pYjQOp